Document Detail


Synthesis, characterization and paclitaxel release from a biodegradable, elastomeric, poly(ester urethane)urea bearing phosphorylcholine groups for reduced thrombogenicity.
MedLine Citation:
PMID:  23035885     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Biodegradable polymers with high elasticity, low thrombogenicity and drug loading capacity continue to be pursued for vascular engineering applications, including vascular grafts and stents. A biodegradable elastomeric polyurethane was designed as a candidate material for use as a drug-eluting stent coating, such that it was non-thrombogenic and could provide anti-proliferative drug release to inhibit smooth muscle cell proliferation. A phosphorylcholine containing poly(ester urethane) urea (PEUU-PC) was synthesized by grafting aminated phosphorylcholine onto backbone carboxyl groups of a polyurethane (PEUU-COOH) synthesized from a soft segment blend of polycaprolactone and dimethylolpropionic acid, a hard segment of diisocyanatobutane and a putrescine chain extender. Poly(ester urethane) urea (PEUU) from a soft segment of polycaprolactone alone was employed as a control material. All of the synthesized polyurethanes showed high distensibility (>600%) and tensile strengths in the 20-35 MPa range. PEUU-PC experienced greater degradation than PEUU or PEUU-COOH in either a saline or lipase enzyme solution. PEUU-PC also exhibited markedly inhibited ovine blood platelet deposition compared with PEUU-COOH and PEUU. Paclitaxel loaded in all of the polymers during solvent casting continued to release for 5 d after a burst release in a 10% ethanol/PBS solution, which was utilized to increase the solubility of the releasate. Rat smooth muscle cell proliferation was significantly inhibited in 1 wk cell culture when releasate from the paclitaxel-loaded films was present. Based on these results, the synthesized PEUU-PC has promising functionality for use as a non-thrombogenic, drug eluting coating on metallic vascular stents and grafts.
Authors:
Yi Hong; Sang-Ho Ye; Anca L Pelinescu; William R Wagner
Related Documents :
16637795 - Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastas...
22121085 - Morphological and degradation studies of sirolimus-containing poly(lactide-co-glycolide...
18005375 - Pharmacokinetics of intraperitoneally instilled aminophylline, terbutaline and tobramyc...
12703615 - Pharmacodynamics of isoflupredone acetate in an endotoxin-induced mastitis model.
20446865 - Oxazaphosphorines: new therapeutic strategies for an old class of drugs.
20524815 - Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regula...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-4
Journal Detail:
Title:  Biomacromolecules     Volume:  -     ISSN:  1526-4602     ISO Abbreviation:  Biomacromolecules     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100892849     Medline TA:  Biomacromolecules     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prediction of Preeclampsia: Liver Function Tests during the First 20 Gestational Weeks.
Next Document:  Dietary and Supplemental Folate and the Risk of Left- and Right-Sided Colorectal Cancer.